Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway

Area of Science:

• Molecular Biology
• Oncology
• Cell Biology

Background:

• Angiomotin (AMOT) is a protein family involved in cell junctions and neurofibromatosis type 2.
• The role of AMOT in prostate cancer (PCa) remains largely unexplored.
• AMOT exists as two isoforms, AMOTp80 and AMOTp130, with distinct structures and potential functions.

Purpose of the Study:

• To investigate the role of Angiomotin (AMOT) isoforms in prostate cancer (PCa).
• To elucidate the specific functions of AMOTp80 and AMOTp130 in PCa cells.
• To uncover the molecular mechanisms underlying AMOT's influence on PCa progression.

Main Methods:

• Differential expression analysis of AMOT isoforms in various PCa cell lines.
• Functional assays to assess the impact of AMOTp80 and AMOTp130 on PCa cell proliferation.
• Mechanistic studies involving the Hippo pathway, YAP, and BMP4 signaling.
• Pharmacological inhibition of BMP receptor activity.

Main Results:

• AMOTp80 and AMOTp130 are differentially expressed in PCa cell lines, with low levels in aggressive lines.
• AMOTp80 significantly enhances PCa cell proliferation, while AMOTp130 does not.
• AMOTp80 promotes YAP nuclear translocation via the Hippo pathway, increasing BMP4 expression.
• Inhibition of BMP receptor activity blocks AMOTp80-driven proliferation.

Conclusions:

• The AMOTp80 isoform acts as a tumor promoter in prostate cancer.
• AMOTp80 drives proliferation through the Merlin-MST1-LATS-YAP-BMP4 signaling axis.
• This study identifies a novel pathway contributing to prostate cancer development and progression.